Modafinil is a vigilance promoting drug (or eugeroic) that is approved by the United States' Food and Drug Administration (FDA) for treatment of the wakefulness disorders of narcolepsy, shift work sleep disorder and excessive daytime sleepiness associated with obstructive sleep apnea. In English-speaking countries it is sold under the brand names: Alertec (CA), Modavigil (AU, NZ) and Provigil (IE, ZA, UK, US).
Multiple sclerosis
Modafinil has also found off-label use with the neurological fatigue reported by some with multiple sclerosis.[51] In 2000, Cephalon conducted a study to evaluate modafinil as a potential treatment for MS-related fatigue. A group of 72 people with MS of varying degrees of severity tested two different doses of modafinil and an inactive placebo over nine weeks. Fatigue levels were self-evaluated on standardized scales. Participants taking a lower dose of modafinil reported feeling less fatigued and there was a statistically significant difference in fatigue scores for the lower dose versus the placebo. The higher dose of modafinil was not reported to be significantly more effective.
Hyland, MJ (May 3, 2013). "The drugs do work: my life on brain enhancers | Life and style"
. London: The Guardian. Retrieved December 31, 2013.
Jump up^ Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN (February 2002). "Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study"
. J. Neurol. Neurosurg. Psychiatr. 72 (2): 179–83. doi:10.1136/jnnp.72.2.179
.PMC 1737733
. PMID 11796766
.
Jump up^ Frost J, Okun S, Vaughan T, Heywood J, Wicks P (2011). "Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMe"
. Journal of Medical Internet Research 13 (1): e6.doi:10.2196/jmir.1643
. PMC 3221356
. PMID 21252034
.
No comments:
Post a Comment